Interventions for deliberately altering blood pressure in acute stroke
Abstract
Background
It is unclear whether blood pressure should be altered actively during the acute phase of stroke. This is an update of a Cochrane review first published in 1997, and previously updated in 2001.
Objectives
To assess the effect of altering blood pressure in people with acute stroke, and the effect of different vasoactive drugs on blood pressure in acute stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (last searched July 2007), the Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2 2008), MEDLINE, EMBASE and other databases, reference lists of relevant publications and contacted researchers in the field.
Selection criteria
Randomised controlled trials of interventions that aimed to alter blood pressure in patients within one week of acute ischaemic or haemorrhagic stroke.
Data collection and analysis
Two review authors independently applied the inclusion criteria, assessed trial quality and extracted data.
Main results
Twelve trials involving 1153 participants were included (603 participants were assigned active therapy and 550 participants received placebo/control). The trials tested angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARA), calcium channel blockers (CCBs), clonidine, glyceryl trinitrate (GTN), thiazide diuretic and mixed antihypertensive therapy. One trial tested phenylephrine. At 24 hours after randomisation ACEIs reduced systolic blood pressure (SBP, mean difference, MD ‐6 mmHg, 95% confidence interval, CI ‐22 to 10) and diastolic blood pressure (DBP, MD ‐5 mmHg, 95% CI ‐18 to 7), ARA reduced SBP (MD ‐3, 95% CI ‐7 to 2) and DBP (MD ‐3, 95% CI ‐6 to 0.4), iv CCBs reduced SBP (MD ‐32 mmHg, 95% CI ‐65 to 1) and DBP (MD ‐13 mmHg, 95% CI ‐31 to 6), oral CCBs reduced SBP (MD ‐13 mmHg, 95% , CI ‐43 to 17) and DBP (MD ‐6 mmHg, 95% CI ‐14 to 2), GTN reduced SBP (MD ‐10 mmHg, 95% CI ‐18 to ‐3) and DBP (MD ‐1 mmHg, 95% CI ‐5 to 3) while phenylephrine, non‐significantly increased SBP (MD 21 mmHg, 95% CI ‐13 to 55) and DBP (MD 1 mmHg, 95% CI ‐15 to 16). Functional outcome and death were not altered by any of the drugs.
Authors' conclusions
There is insufficient evidence to evaluate the effect of altering blood pressure on outcome during the acute phase of stroke. In patients with acute stroke, CCBs, ACEI, ARA and GTN each lower blood pressure while phenylephrine probably increases blood pressure.
PICO
Plain language summary
Interventions for deliberately altering blood pressure in acute stroke
In patients who have just had a stroke (a sudden brain attack either due to blockage or rupture of an artery in the brain), very high and very low blood pressures may be harmful. Drugs which raise low blood pressure or lower high blood pressure might benefit patients with acute stroke. This review looked at those trials which deliberately altered blood pressure, either up or down. Twelve trials involving 1153 participants are included in the review: 11 trials that lowered blood pressure and one trial that raised blood pressure. There was not enough evidence to decide if drugs that lower or raise blood pressure should be used in the treatment of acute stroke. More research is needed and several trials are ongoing.
